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Dysfunction of the blood-brain barrier (BBB) is a primary characteristic of experimental autoimmune encephalomyelitis (EAE),
an experimental model of multiple sclerosis (MS). Matrine (MAT), a quinolizidine alkaloid derived from the herb Radix Sophorae
Flave, has been recently found to suppress clinical EAE and CNS inflammation. However, whether this effect of MAT is through
protecting the integrity and function of the BBB is not known. In the present study, we show that MAT treatment had a therapeutic
effect comparable to dexamethasone (DEX) in EAE rats, with reduced Evans Blue extravasation, increased expression of collagen
IV, the major component of the basement membrane, and the structure of tight junction (TJ) adaptor protein Zonula occludens-1
(ZO-1). Furthermore, MAT treatment attenuated expression of matrix metalloproteinase-9 and -2 (MMP-9/-2), while it increased
the expression of tissue inhibitors of metalloproteinase-1 and -2 (TIMP-1/-2). Our findings demonstrate that MAT reduces BBB
leakage by strengthening basement membrane, inhibiting activities of MMP-2 and -9, and upregulating their inhibitors. Taken
together, our results identify a novel mechanism underlying the effect of MAT, a natural compound that could be a novel therapy
for MS.
1. Introduction
Multiple sclerosis (MS) and its animal model, experimental
autoimmune encephalomyelitis (EAE), are T cell-mediated
inflammatory diseases characterized by lymphocyte infiltra-
tion, demyelination, and axonal injury [1, 2]. Although MS
pathology is not fully understood, blood-brain barrier (BBB)
dysfunction plays an essential role in the pathogenesis of this
disease. In both MS and EAE, proinflammatory cells and
toxic molecules migrate into the brain via the damaged BBB,
resulting in cerebral edema, demyelination, and neural cell
death [3, 4].
The BBB is composed of basement membrane, interen-
dothelial tight junctions (TJs), and perivascular astrocytes
[5]. The basement membrane, which is composed of two
distinct types, namely, endothelial basement membrane and
parenchymal basement membrane, is a tight assembly of
specialized extracellular matrix molecules [6]. This mem-
brane, together with the endothelial cell monolayer, forms
a structural barrier that selectively filters blood elements
[6, 7]. Collagen IV comprises 90% of total protein in the
basement membrane and plays a decisive role in maintaining
the structural integrity of the vessel wall [8, 9]. Collagen IV,
as a major component of the cerebral microvascular basal
lamina, is widely used as a marker to determine the extent
of destruction of the basement membrane.
TJs, composed of large multiprotein complexes, seal the
gaps between biological barriers [4]. Altered distribution or
loss of TJs is frequently seen in ischemic cerebral microves-
sels, resulting in diminished BBB integrity [10]. Zonula
occludens-1 (ZO-1) is the primary cytoplasmatic protein
associated with TJs, which links the C-terminal ends of
occludin and claudins to the underlying actin cytoskeleton
[7]. A decrease in ZO-1 expression results in increased BBB
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permeability [11]. In addition, disease severity during the
acute phase of EAE is directly associated with the extent of
BBB permeability [12].
It has been shown that BBB disruption is accompanied
by excessive expression ofmatrixmetalloproteinases (MMPs)
[13]. MMPs, including MMP-9 andMMP-2, belong to a class
of zinc-bound proteases, whose functions include induction
of inflammation, cleavage of myelin proteins, activation
or degradation of disease-modifying cytokines, and direct
damage to CNS cells [14]. Abnormal increases in MMP-
9 and MMP-2 in endothelial cells may collectively impair
endothelial barrier function by degrading the vascular base-
ment membrane and TJs [10, 14, 15]. Furthermore, MMP-9
andMMP-2 are upregulated in the CNS of rat models of EAE
[16].
Tissue inhibitors of metalloproteinases (TIMPs) are
endogenous inhibitors of MMPs. TIMP-1 controls MMP-9
activity through high affinity, noncovalent binding to the
MMP catalytic domain, whereas MMP-2 is bound by TIMP-
2 [17]. It has been shown that TIMP-1 deficiency enhances
disease severity during EAE [18]. Under normal physiological
conditions, there is a constant balance between MMP and
TIMP activity, which is essential in maintaining the physio-
logical functions of the organism [19]. In contrast, an imbal-
ance in MMP/TIMP ratio is found in various pathological
conditions in humans, such as cancer, rheumatoid arthritis,
and vascular diseases [20]. For example, the serum MMP-
9/TIMP-1 ratio in relapsing-remitting MS patients correlates
with development of the disease [17]. An imbalance between
MMP-2 and TIMP-2 caused by radiation plays a role in the
pathogenesis of brain injury [21].
Currently, treatment of MS is limited to immunomod-
ulatory or immunosuppressive therapy, which is not always
successful and often has severe side effects [22]. Hence, the
search for more effective and more tolerable compounds is
of great importance. Matrine (MAT) is a natural alkaloid
component extracted from the herb Radix Sophorae Flaves,
with a MW of 258.43 (C
15
H
24
N
2
O, Figure 1(a)). It has been
reported that MAT suppressed immune activities of T cells,
B cells, and macrophages [23]. Matrine has long been used
for the treatment of viral hepatitis, cardiac arrhythmia, and
skin inflammation, without known side effects [24, 25].While
MAT suppressed development of EAE, its mechanism for
neuroprotection has not been elucidated.The purpose of this
study was to determine whetherMAT treatment inhibits BBB
disruption by reducing BBB leakage, strengthening the base-
ment membrane, enhancing TJs, and regulating the balance
between MMPs and TIMPs during disease progression of
EAE.
2. Materials and Methods
2.1. Animals. Female, 6-7 week-old Wistar rats were pur-
chased from Shanghai Xipuer-Bikai Experimental Animal
Company, China, and housed in the aseptic laboratory of
the Experimental Animal Center of Henan, China. All efforts
were made to minimize the numbers of animals used and to
ensure minimal suffering.
2.2. EAE Induction and Treatment. EAE was induced as
described previously [23] with only minor modifications.
Spinal cord homogenate of guinea pig (Experimental Animal
Center of Hebei) weighing 300–350 g was emulsified with the
same volume of complete Freund’s adjuvant (CFA) (Sigma,
USA) containing 6mg/mL Bacillus Calmette-Gue´rin vaccine
(Shanghai Institute of Biological Products, China). Each rat
received a subcutaneous injection of 0.5mL emulsion divided
among 5 sites draining into the nape and back. All procedures
were approved by the Bioethics Committee of Zhengzhou
University.
Immunized rats were randomly divided into four groups
(𝑛 = 16 each group) for different treatments. Briefly, MAT
(Jiangsu Chia Tai Tianqing Pharmaceutical Co., Jiangsu,
China) was dissolved in normal saline and injected intraperi-
toneally (i.p.) daily at two doses: low (150mg/kg; MAT-L)
and high (250mg/kg; MAT-H), the dosage calculated at
6.7mL/kg, from day 1 until day 17 after immunization (p.i.).
Dexamethasone (DEX) (Henan Hongrun Pharmaceutical
Co., Henan, China), as the positive control drug, was dis-
solved in normal saline (6.7mL/kg) and injected (i.p.) daily,
from day 1 until day 17 p.i. at 1mg/kg. Immunized rats that
received the same amount of normal saline only i.p. served
as a vehicle control, and 16 nonimmunized naive rats that
received the same amount of normal saline i.p. served as the
naive group.
2.3. Clinical Scoring and Weight. Rats were monitored and
weighed daily by two independent observers to evaluate
clinical scores of EAE after immunization. Neurological signs
were assessed as follows [23]: 0 = no clinical score; 1 = loss of
tail tone; 2 = hind limb weakness; 3 = hind limb paralysis; 4
= forelimb paralysis; 5 = moribund or death.
2.4. Histopathological Evaluation. On day 17 p.i., two inde-
pendent observers randomly selected 8 rats from each group.
When animals were sacrificed, sera and spinal cords were
collected after extensive perfusion. The lumbar enlargement
of spinal cords was embedded in paraffin. After embed-
ding, 2-3 𝜇m thick sections were prepared and stained with
hematoxylin-eosin (HE) for inflammatory infiltration and
chromotrope 2R-brilliant green (C-2R-B) for demyelination.
Histopathological examination was performed and scored
in a blinded fashion as follows [22]: for inflammation: 0,
no inflammatory cells; 1, a few scattered inflammatory cells;
2, organization of inflammatory infiltrates around blood
vessels; 3, extensive perivascular cuffing with extension into
adjacent parenchyma, or parenchyma; for demyelination: 0,
none; 1, rare foci; 2, a few areas of demyelination; 3, large
(confluent) areas of demyelination.
2.5. Evaluation of BBB Leakage. BBB leakage was assessed
using Evans Blue (EB) dye as previously described [26].
On day 17 p.i., the 8 rats remaining in each group were
anesthetized. EB dye (2%; 4mL/kg; Sigma, St. Louis, MO,
USA) was injected slowly into the tail vein and was allowed
to circulate for 60 minutes. When the rats were sacrificed,
brains were removed and immediately weighed. The EB
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Figure 1: MAT reduces clinical signs of EAE. (a) Structure of MAT. (b) Effect-versus-time curves of MAT effects on EAE. Clinical EAE was
scored daily after immunization according to a 0–5 scale. (c) The mean maximum clinical scores are expressed as mean ± SD (𝑛 = 16 each
group). △△𝑃 < 0.01, compared to naive group; ∗𝑃 < 0.05, compared to vehicle-treated group.
dye was extracted in 2.5mL of PBS, and 2.5mL of 60%
trichloroacetic acid was added. The mixture was then vor-
texed and centrifuged for 40min at 4000 rpm, and the
amount of EB dye in supernatants was determined at 610 nm
by spectrophotometry and quantified to 𝜇g/g brain tissue.
2.6. RT-PCR Analysis of Collagen IV and ZO-1 mRNAs. The
cervical spinal cords were harvested on day 17 p.i. and were
prepared for analysis of collagen IV and ZO-1 mRNA using
real-time polymerase chain reaction (PCR). Total cellular
RNA from these tissues was isolated using TRIzol reagent
(Beijing TransGen Biotech Co., Beijing, China) following
the standard protocol. cDNA synthesis was performed by
reverse transcription using a Promega reverse transcription
kit. The cDNA copy number for each gene was determined
using standard curves of the corresponding PCR product.
Primers for collagen IV were 5󸀠-GGCCCCTGCTGAAG-
CGTT-3󸀠 (forward) and 5󸀠-GTTCCCCGAGCACCTTAG-3󸀠
(reverse), which produced a 306 bp PCR product. Primers
for ZO-1 were 5󸀠-CCATCTTTGGACCGATTGCTG-3󸀠 (for-
ward) and 5󸀠-TAATGCCCGAGCTCCGATG-3󸀠 (reverse),
which produced a 372 bp PCR product. Gene expres-
sion was normalized to expression of the endogenous
housekeeping gene 𝛽-actin. The 𝛽-actin primers were
5󸀠-CCTCTGAACCCTAAGGCCAAC-3󸀠 (forward) and 5󸀠-
TGCCACAGGATTCCATACC-3󸀠 (reverse), which produced
a 564 bp PCR product. To determine the relative quantifica-
tion of target gene expression, we used the gel imaging anal-
ysis system (Dalian Jingmai Biotech Co., Liaoning, China).
2.7. ELISA Analysis of MMP-9 and TIMP-1. Serum collected
on day 17 p.i. was assayed for concentrations of MMP-9 and
TIMP-1 by ELISA following the manufacturer’s instructions
(R & D Systems, USA). Samples were quantified by compar-
ison with the standard curves of MMP-9 and TIMP-1 (0–
200 ng/mL).
2.8. Immunohistochemical Analysis of MMP-2 and TIMP-2.
Paraffin-embedded tissue of spinal cords from each group
was cut into 5𝜇m thick sections. Immunohistochemistry
was performed on these slices, using anti-rat antibodies for
MMP-2 and TIMP-2 (all from Beijing TransGen Biotech
Co.; Beijing, China). Sections were rinsed and incubated
in nonbiotinylated goat anti-rabbit IgG secondary antibody.
The chromophore product was developed using a Simple
Stain DAB solution (Beijing TransGen Biotech Co., Beijing,
China). The integral optical density (IOD) of positive cells in
a restricted area was determined to represent the expressions
ofMMP-2 and TIMP-2 using BiosensDigital Imaging System
v1.6.
2.9. Statistical Analysis. All data are presented as mean ±
SD. Statistical analysis was performed with SPSS 16.0 (SPSS,
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Table 1: Mean maximum clinical scores and body weight on day 17
p.i.
Groups Body weight (g) (mean ± SD) (𝑛 = 16)
Naive control 224.38 ± 13.99
Vehicle-treated group 154.63 ± 10.83△△
MAT-L 173.56 ± 11.03∗∗##◊
MAT-H 182.31 ± 10.12∗∗##◊
DEX 145.68 ± 9.89∗
△△
𝑃 < 0.01, compared to the naive group; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01,
compared to vehicle-treated group; ##𝑃 < 0.01, compared to DEX group;
◊
𝑃 < 0.05, comparison between MAT-L group and MAT-H group.
Chicago, USA). Multiple comparisons were performed using
the Kruskal-Wallis test, or ANOVA, followed by the LSD-t
test, as appropriate. A 𝑃 value less than 0.05 was considered
significant.
3. Results
3.1. MAT Treatment Alleviates Clinical Severity of EAE. In the
vehicle-treated group, clinical decline typically started on day
10 p.i., while EAE onset for MAT-treated rats occurred on
day 12 p.i. (low dose) and 13 p.i. (high dose) (Figure 1(b)).
Compared to the vehicle-treated group, both MAT-treated
groups exhibited significantly lower mean maximum clinical
scores (Figure 1(c)) and body weight loss (Table 1). Treatment
with DEX also delayed disease progression and reduced
clinical scores compared to the vehicle-treated group (𝑃 <
0.05). There was no significant difference between animals
treated with DEX and the two different doses of MAT.
3.2. Effect of MAT Treatment on CNS Histopathology. To
assess EAE neuropathology, lumbar enlargements of spinal
cord samples were examined using H&E and myelin staining
(Figure 2). Perivascular cuffing with mononuclear cells and
infiltration into CNS parenchymawere observed in the spinal
cord of rats in the vehicle-treated group (Figure 2), while the
extent of cellular infiltration was significantly decreased in
the MAT-treated groups (both 𝑃 < 0.01). Treatment with
DEX showed a stronger inhibition in cellular infiltration than
MAT-treated groups (both 𝑃 < 0.01). Cellular infiltration
was not observed in the naive group. Moreover, as shown in
Figure 2, large areas of demyelination were observed in the
vehicle-treated group, while MAT- and DEX-treated groups
exhibited only a few areas of demyelination. No significant
difference in demyelination was observed between MAT-H
and DEX groups.
3.3. MAT Inhibits Evans Blue (EB) Leakage through the BBB.
Destruction of the BBB is one of the important features ofMS
and EAE. We quantified the extravasation of EB dye into the
brain as an indicator of BBB permeability. EB extravasation
into the brain of vehicle-treated EAE rats was significantly
higher than in naive brain (𝑃 < 0.01) (Figure 3). The content
of EB was significantly decreased in MAT- and DEX-treated
groups compared to the vehicle-treated group (all 𝑃 < 0.01),
while a more profound decrease in EB content was observed
in rats treated with MAT-H and DEX than with MAT-L (𝑃 <
0.05). No significant difference was observed between those
treated with high doses of MAT and DEX.
3.4. MAT Protects Collagen IV and ZO-1 mRNA Expression.
To determine the basement membrane disruption, we eval-
uated mRNA expression of collagen IV, a major component
of the cerebralmicrovascular basementmembrane, using RT-
PCR analysis. As shown in Figure 4(a), the brightest bandwas
exhibited in the naive group,while the faintest bandwas in the
vehicle-treated group, consistent with quantitative analysis
(Figure 4(c)). A dose-dependent increase in collagen IV
expression was observed in MAT-treated groups. While the
MAT-L-treated group showed lower collagen IV expression
than the DEX group (𝑃 < 0.01), there was no significant
difference between MAT-H and DEX groups.
We also assessed ZO-1mRNA expression to determine TJ
disruption. A similar pattern of mRNA expression of ZO-1
was observed for collagen IV (Figures 4(b) and 4(c)).
3.5. MAT Adjusts the Balance between MMP-9 and TIMP-1
in Serum. Serum concentration of MMP-9 was measured by
ELISA. The amount of MMP-9 was dramatically increased
in the vehicle-treated group compared to the naive group
(𝑃 < 0.01) (Figure 5). MAT treatment largely reduced MMP-
9 content compared to the vehicle-treated group (both 𝑃 <
0.01), and the effect was dose dependent. Furthermore, a
significantly lower amount of MMP-9 was observed in the
DEX-treated group than in the MAT-treated groups (𝑃 <
0.01).
We also measured serum concentrations of TIMP-1 in
the different groups. Figure 5 shows a significant decrease in
TIMP-1 concentration in the vehicle-treated group compared
to the naive group (𝑃 < 0.01). TIMP-1 serum levels in the
MAT-treated groups were significantly higher than in the
vehicle-treated group (both 𝑃 < 0.01). While a low dose of
MAT induced a lower serum TIMP-1 level than DEX (𝑃 <
0.01), a high dose of MAT increased the serum TIMP-1 level
to a greater extent than DEX (𝑃 < 0.01).
3.6. MAT Regulates the Balance between MMP-2 and TIMP-
2 in the CNS. To determine the MMP-2/TIMP-2 balance in
the CNS, their expression in the spinal cord was measured
by immunohistochemistry. As shown in Figure 6, MMP-2
expression was significantly increased in the vehicle-treated
group over the naive group (𝑃 < 0.01). The differences
in MMP-2 expression between vehicle-treated and the two
MAT-treated groups were significant (both 𝑃 < 0.01).
Furthermore, the effect of DEX in decreasingMMP-2 content
was stronger than low-dose MAT (𝑃 < 0.05), but there was
no significant difference compared with the MAT-H group.
We then measured TIMP-2 content using the same
method. As shown in Figure 6, TIMP-2 expression in the
vehicle-treated groupwas significantly lower than in the naive
group (𝑃 < 0.01) and MAT-treated groups (𝑃 < 0.05–
0.01). A significantly lower amount was obtained in theMAT-
L group than in the MAT-H group (𝑃 < 0.05). While the
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Figure 2: CNS infiltration and demyelination. At day 17 p.i., spinal cord lumbar enlargements were harvested and transverse sections were
stained with H&E and C-2R-B. (a) Digital images were collected under bright-field setting using a ×40 objective. (b) Quantitative analysis.
Mean values and SD are shown (𝑛 = 8 each group). △△𝑃 < 0.01, compared to naive group; ∗∗𝑃 < 0.01, compared to vehicle-treated group;
#
𝑃 < 0.05 and ##𝑃 < 0.01, compared to DEX group; ◊𝑃 < 0.05 and ◊◊𝑃 < 0.01, comparison between MAT-L and MAT-H groups.
MAT-L-treated group showed lower TIMP-2 expression than
the DEX-treated group (𝑃 < 0.05), there was no significant
difference between MAT-H and DEX groups.
4. Discussion
Although administration of MAT reduced CNS inflamma-
tory infiltration and demyelination, the effect of this natural
compound on the BBB has not yet been studied. In the
present study, we provide evidence that the therapeutic effect
of MAT is, at least partially, through its strengthening of BBB
integrity, its protection of the basement membrane as well as
TJ proteins, and its ability to regulate the balance between
MMPs and TIMPs in both the periphery and CNS.
BBB destruction has been implicated in many CNS dis-
eases, such as MS and stroke [4, 11]. In MS patients and in the
EAE model, breakdown of the BBB is an early critical event,
which is associated with the influx of inflammatory cells and,
ultimately, with a poor outcome [3]. We thus quantified the
extravasation of EB dye into the brain as an indicator of BBB
permeability. Indeed, our study showed that EB leakage was
markedly increased in the EAE model, which was associated
with a decrease in collagen IV andZO-1 expression in vehicle-
treated rats compared to naive rats. MAT treatment largely
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Figure 3: BBB integrity. Evans Blue was i.v. injected at day 17
p.i. and brains were harvested at 60min to determine Evans Blue
extravasation. Results are expressed as mean ± SD (𝑛 = 8 each
group). △△𝑃 < 0.01, compared to naive group; ∗∗𝑃 < 0.01,
compared to vehicle group; ##𝑃 < 0.01, compared to DEX group;
◊
𝑃 < 0.05, comparison between MAT-L and MAT-H groups.
and significantly decreased EB content in the brain compared
with the vehicle group. Together, these results demonstrate
that BBB integrity is compromised during the development
of EAE and that MAT treatment protects the BBB.
BBB integrity depends on adequate structural support
from the basement membranes, and collagen IV comprises
up to 90% of total protein in the basement membrane [7].
In addition, collagen IV is critical for cell signaling by the
interaction with various receptors and adhesion molecules,
and its expression is therefore a marker of barrier damage
and impairment [27]. A study by Lee et al. clearly shows that
degradation of collagen IV has a role in the pathogenesis
of BBB destruction and brain injury [28]. To date, it is
not known whether decreased collagen IV contributes to
BBB damage caused by EAE. We have shown in the present
study that expression of collagen IV mRNA was significantly
decreased in the vehicle-treated group compared to the
naive group, and a dose-dependent increase of collagen IV
mRNA expression was observed in MAT-treated groups.
These results indicate that collagen IV degradation plays an
important role in BBB disruption and that MAT treatment
effectively preserves the content of collagen IV.
In the BBB, TJs are composed of large multiprotein
complexes that mediate tight intercellular contacts among
adjacent cells and play a critical role inmaintainingBBB func-
tion by improving the barrier function at the endothelial level
[29]. Previous publications have reported varying degrees
of TJ pathology in EAE [30, 31]. Bennett et al. found that
relocalization of ZO-1, which is a multidomain polypeptide
required for the assembly of TJs [32], precedes disease onset
and correlates with CNS infiltration in EAE [33]. Similar
to these observations, our study found a decrease in ZO-1
mRNA expression in vehicle-treated group compared to the
naive group and that ZO-1 mRNA levels were significantly
improved with MAT treatment in a dose-dependent manner.
These results are consistent with preserved collagen IV levels
and indicate a protected BBB basement membrane.
In order to further study the mechanism of BBB protec-
tion induced by MAT treatment, we evaluated the activity
and balance of MMPs and TIMPs. MMPs, a group of
zinc-containing endopeptidases, cleave most components
of the basement membrane including fibronectin, laminin,
proteoglycans, and collagen IV [34, 35]. It has been found
that focal MMP-2 and MMP-9 activity is closely associ-
ated with the infiltrating T cells penetrating through the
parenchymal basement membrane [5, 6]. Upregulation of
MMP-2 and MMP-9 resulted in the degradation of TJs
after focal ischemia/reperfusion, which can be reversed by
MMP inhibition [36, 37]. In addition, a selective upregulation
of MMP-9 in MS disease activity has been described [17].
Similarly, a significant increase in MMP-2 expression in
the central canal of the cervical spinal cord is a sign of
inflammation in acute EAE [38]. Furthermore, among the
MMP family, MMP-9, together with MMP-2, is a member
of the collagenase IV family, which has been implicated in
the degradation of constituents of the basement membranes
[15]. Targeting MMPs and chemokines has been considered
an important therapeutic approach, alone or in combination
with current medications, in enhancing their effect in neu-
rological disorders such as MS [39]. In the present study,
significant upregulation of MMP-9 in serum was observed
in the vehicle-treated group compared to the naive group,
and MAT treatment reduced the levels of MMP-9. Further,
the loss of collagen IV and ZO-1 was reduced by blocking
MMP-9 and MMP-2 in EAE. These studies suggest that
overexpression of MMP-9 and MMP-2 in EAE could have
been a causative agent in the reduced intensity of collagen IV
and ZO-1; MAT treatment inhibition of MMP-9 and MMP-
2 levels will preserve levels of collagen IV and ZO-1 and will
thus be beneficial for BBB integrity.
The active forms of all MMPs are inhibited by a family
of specific inhibitors, tissue inhibitors of metalloproteinases
(TIMPs) [18, 19]. MMP-9 and MMP-2 are preferentially
inhibited by TIMP-1 and TIMP-2, respectively, [17]. It has
been found that normal homeostasis in the CNS requires
a balance between MMPs and TIMPs, while an imbalance
between thesemolecules is often associated with CNS pathol-
ogy [40]. For example, radiation-induced brain injury is
associated with an increased ratio between MMP-2 and
TIMP-2 [21], and a significant increase in theMMP-9/TIMP-
1 ratio also correlates with MS activity [17]. In our study, an
imbalance between MMP-9 and TIMP-1 was observed in the
vehicle-treated EAE group, with upregulation of MMP-9 and
downregulation of TIMP-1; this was also the case for balance
between MMP-2 and TIMP-2. We could speculate that
overexpression of MMP-9/-2 in EAE was counterbalanced
by MAT-mediated increase in TIMP-1/-2 expression, thus
constituting a steady balance of MMPs and TIMPs that can
be attributed to improved BBB function.
To further investigate the therapeutic effects of MAT
on EAE, we compared MAT with DEX, a glucocorticoid,
which was chosen as the positive control drug because of
its strong ability to suppress inflammation. While MAT at
a low dose showed a weaker effect than DEX, a comparable
effect was observed between DEX and MAT-H groups, with
a stronger effect of MAT in improving the TIMP-1 content
in the serum. We believe that MAT would prove to be
superior to DEX, whose long-term use carries with it the risk
Mediators of Inflammation 7
M Naive VehicleDEX MAT-LMAT-H
𝛽-Actin700 bp600 bp
500 bp
400 bp
300 bp
200 bp
100 bp
Collagen IV
(a)
M Naive VehicleDEX MAT-LMAT-H
𝛽-Actin
700 bp
600 bp
500 bp
400 bp
300 bp
200 bp
100 bp
ZO-1
(b)
1.2
0.8
0.4
0.0
Collagen IV ZO-1
󳵻󳵻 󳵻󳵻
∗∗
∗∗
∗∗
∗∗
∗∗
∗∗
⋄⋄
⋄⋄
####
Re
lat
iv
e i
nt
en
sit
y 
to
𝛽
-a
ct
in
Naive
Vehicle
MAT-L
MAT-H
DEX
(c)
Figure 4: Collagen IV and ZO-1 mRNA expression. Spinal cords were harvested from treated and untreated EAE rats at day 17 p.i.; mRNA
expression of collagen IV (a) and ZO-1 (b) was determined by RT-PCR, and an example of bands is shown. (c) Quantitative analysis. Results
are expressed as mean ± SD (𝑛 = 8 each group). △△𝑃 < 0.01, compared to naive group; ∗∗𝑃 < 0.01, compared to vehicle group; ##𝑃 < 0.01,
compared to DEX group; ◊◊𝑃 < 0.01, comparison between MAT-L and MAT-H groups.
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Figure 5: Serum concentration of MMP-9 and TIMP-1. At day
17 p.i., sera were harvested from treated and nontreated EAE rats,
with sera from naive rats serving as control. MMP-9 and TIMP-
1 production was determined by ELISA. Results are expressed as
mean ± SD (𝑛 = 8 each group). △△𝑃 < 0.01, compared to naive
group; ∗∗𝑃 < 0.01, compared to the vehicle group; ##𝑃 < 0.01,
compared to the DEX group; ◊◊𝑃 < 0.01, comparison between
MAT-L and MAT-H groups.
of side effects common to systemic glucocorticoids occur-
ring over a relatively prolonged period. These side effects
include hyperglycemia, hypertension, negative calcium bal-
ance, osteoporosis, weight gain, or even immunodeficiency
[41, 42]. The extensive use of DEX in the treatment of
severe acute respiratory syndrome (SARS) has often resulted
in hypocortisolism and osteonecrosis of the femoral head,
causing patients to lose the ability to work [43]. In contrast,
patients with hepatitis B who used MAT for a long time
showed significant therapeutic effect and good tolerance,
with only minor side effects such as infrequent, transient
dizziness and nausea. Whether long-term use of MAT would
be safer and have fewer side effects than DEX needs further
investigation.
In summary, our study demonstrates that improving
BBB integrity is one of the mechanisms of MAT action
in EAE therapy. This effect is at least partially through
inhibiting activities of MMP-2/-9 and protecting the base-
mentmembranes and tight junction proteins, thus improving
BBB integrity. As a result, inflammatory infiltration into
the CNS is largely reduced, thereby protecting CNS tis-
sues from proinflammatory cell/mediator-induced damage.
While the process of immune cell extravasation is partially
an endothelial cell-mediated process [44], whether MAT
reduces this pathway of immune cell infiltration is not yet
8 Mediators of Inflammation
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Figure 6: Immunohistochemistry of MMP-2 and TIMP-2. At day 17 p.i., spinal cords were harvested after extensive perfusion. (a) MMP-2
and TIMP-2 expression was determined by immunohistochemistry. Magnification: ×40. (b) Quantitative analyses. Values represent mean
± SD (𝑛 = 8 each group). △△𝑃 < 0.01, compared to naive group; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.01, compared to the vehicle group; #𝑃 < 0.05,
compared to the DEX group; ◊𝑃 < 0.05, comparison between MAT-L and MAT-H groups.
known. Nevertheless, results from the present study, together
with the suppressive effect of MAT on Th1/Th17 cells [23]
and its safety, suggest that MAT could qualify as an effective,
alternative medication in MS therapy and that further study
to test this possibility is warranted.
Conflict of Interests
None of the authors have a conflict of interests with any
trademark mentioned in this paper.
Acknowledgments
This study was supported by the Henan Province Science and
Technology Development Plan (no. 122102310229) and grants
from the Experimental Animal Center of Henan, China. The
authors thank Katherine Regan for the editorial assistance.
References
[1] P. S. Rommer andO. Stu¨ve, “Management of secondary progres-
sive multiple sclerosis: prophy- lactic treatment-past, present,
Mediators of Inflammation 9
and future aspect,”Current Treatment Options in Neurology, vol.
15, no. 3, pp. 241–258, 2013.
[2] H. Lassmann, “Axonal and neuronal pathology inmultiple scle-
rosis: what have we learnt from animal models,” Experimental
Neurology, vol. 225, no. 1, pp. 2–8, 2010.
[3] A. H. Badawi, P. Kiptoo, W.-T. Wang et al., “Suppression
of EAE and prevention of blood-brain barrier breakdown
after vaccination with novel bifunctional peptide inhibitor,”
Neuropharmacology, vol. 62, no. 4, pp. 1874–1881, 2012.
[4] F. Pfeiffer, J. Scha¨fer, R. Lyck et al., “Claudin-1 induced sealing of
blood-brain barrier tight junctions ameliorates chronic exper-
imental autoimmune encephalomyelitis,” Acta Neuropatholog-
ica, vol. 122, no. 5, pp. 601–614, 2011.
[5] L. Sorokin, “The impact of the extracellular matrix on inflam-
mation,” Nature Reviews Immunology, vol. 10, no. 10, pp. 712–
723, 2010.
[6] S. Agrawal, P. Anderson, M. Durbeej et al., “Dystroglycan is
selectively cleaved at the parenchymal basement membrane at
sites of leukocyte extravasation in experimental autoimmune
encephalomyelitis,” Journal of Experimental Medicine, vol. 203,
no. 4, pp. 1007–1019, 2006.
[7] B. T. Hawkins and T. P. Davis, “The blood-brain barrier/neuro-
vascular unit in health and disease,” Pharmacological Reviews,
vol. 57, no. 2, pp. 173–185, 2005.
[8] G. F. Hamann, M. Liebetrau, H. Martens et al., “Microvascular
basal lamina injury after experimental focal cerebral ischemia
and reperfusion in the rat,” Journal of Cerebral Blood Flow &
Metabolism, vol. 22, no. 5, pp. 526–533, 2002.
[9] F. A. Sehba, G. Mostafa, J. Knopman, V. Friedrich Jr., and J.
B. Bederson, “Acute alterations in microvascular basal lamina
after subarachnoid hemorrhage,” Journal of Neurosurgery, vol.
101, no. 4, pp. 633–640, 2004.
[10] J. Liu, X. Jin, K. J. Liu, and W. Liu, “Matrix metalloproteinase-
2-mediated occludin degradation and caveolin-1-mediated
claudin-5 redistribution contribute to blood-brain barrier dam-
age in early ischemic stroke stage,” Journal of Neuroscience, vol.
32, no. 9, pp. 3044–3057, 2012.
[11] M. Khan, T. S. Dhammu, H. Sakakima et al., “The inhibitory
effect of S-nitroso-glutathione on blood-brain barrier disrup-
tion and peroxynitrite formation in a rat model of experimental
stroke,” Journal of Neurochemistry, vol. 123, no. 2, pp. 86–97,
2012.
[12] J. Bennett, J. Basivireddy, A. Kollar et al., “Blood-brain barrier
disruption and enhanced vascular permeability in the multiple
sclerosismodel EAE,” Journal of Neuroimmunology, vol. 229, no.
1-2, pp. 180–191, 2010.
[13] S. M. Gold, M. V. Sasidhar, L. B. Morales et al., “Estrogen
treatment decreases matrix metalloproteinase (MMP)-9 in
autoimmune demyelinating disease through estrogen receptor
alpha (ER𝛼),” Laboratory Investigation, vol. 89, no. 10, pp. 1076–
1083, 2009.
[14] L. D. Kandagaddala, M.-J. Kang, B. C. Chung, T. A. Patter-
son, and O.-S. Kwon, “Expression and activation of matrix
metalloproteinase-9 andNADPH oxidase in tissues and plasma
of experimental autoimmune encephalomyelitis in mice,”
Experimental andToxicologic Pathology, vol. 64, no. 1-2, pp. 109–
114, 2012.
[15] A. W. Clark, C. A. Krekoski, S.-S. Bou, K. R. Chapman, and D.
R. Edwards, “Increased gelatinase A (MMP-2) and gelatinase
B (MMP-9) activities in human brain after focal ischemia,”
Neuroscience Letters, vol. 238, no. 1-2, pp. 53–56, 1997.
[16] X.Ma, Y. Jiang, A.Wu et al., “Berberine attenuates experimental
autoimmune encephalomyelitis in C57 BL/6 mice,” PLoS One,
vol. 5, no. 10, Article ID e13489, 2010.
[17] C. Avolio,M. Filippi, C. Tortorella et al., “SerumMMP-9/TIMP-
1 andMMP-2/TIMP-2 ratios in multiple sclerosis: relationships
with different magnetic resonance imaging measures of disease
activity during IFN-beta-1a treatment,” Multiple Sclerosis, vol.
11, no. 4, pp. 441–446, 2005.
[18] M. Thorne, C. S. Moore, and G. S. Robertson, “Lack of TIMP-1
increases severity of experimental autoimmune encephalomy-
elitis: effects of darbepoetin alfa on TIMP-1 null and wild-type
mice,” Journal of Neuroimmunology, vol. 211, no. 1-2, pp. 92–100,
2009.
[19] E. Lambert, E. Dasse´, B. Haye, and E. Petitfre`re, “TIMPs as
multifacial proteins,” Critical Reviews in Oncology/Hematology,
vol. 49, no. 3, pp. 187–198, 2004.
[20] I. Tency, H. Verstraelen, I. Kroes et al., “Imbalances between
matrix metalloproteinases (MMPs) and tissue inhibitor of
metalloproteinases (TIMPs) in maternal serum during preterm
labor,” PLoS One, vol. 7, no. 11, Article ID e49042, 2012.
[21] W. H. Lee, J. P. Warrington, W. E. Sonntag, and Y. W. Lee,
“Irradiation alters MMP-2/TIMP-2 system and collagen type
IV degradation in brain,” International Journal of Radiation
Oncology Biology Physics, vol. 82, no. 5, pp. 1559–1566, 2012.
[22] Q. C. Kan, L. Zhu, N. Liu, and G. X. Zhang, “Matrine suppresses
expression of adhesion molecules and chemokines as a mech-
anism underlying its therapeutic effect in CNS autoimmunity,”
Immunologic Research, vol. 56, no. 1, pp. 189–196, 2013.
[23] X. Zhao, Q. Kan, L. Zhu, and G.-X. Zhang, “Matrine sup-
presses production of IL-23/IL-17 and ameliorates experimental
autoimmune encephalomyelitis,” American Journal of Chinese
Medicine, vol. 39, no. 5, pp. 933–941, 2011.
[24] L. Zhang, T.Wang, X.Wen et al., “Effect ofmatrine onHeLa cell
adhesion and migration,” European Journal of Pharmacology,
vol. 563, no. 1-3, pp. 69–76, 2007.
[25] Z. Wang, J. Zhang, Y. Wang et al., “Matrine, a novel autophagy
inhibitor, blocks trafficking and the proteolytic activation of
lysosomal proteases,” Carcinogenesis, vol. 34, no. 1, Article ID
138, p. 128, 2013.
[26] X. N. Huang, J. Fu, and W. Z. Wang, “The effects of fasudil on
the permeability of the rat blood-brain barrier and blood-spinal
cord barrier following experimental autoimmune encephalo-
myelitis,” Journal of Neuroimmunology, vol. 239, no. 1-2, pp. 61–
67, 2011.
[27] D. Ferna´ndez-Lo´pez, J. Faustino, R. Daneman et al., “Blood-
brain barrier permeability is increased after acute adult stroke
but not neonatal stroke in the rat,”The Journal of Neuroscience,
vol. 32, no. 28, pp. 9588–9600, 2012.
[28] W. H. Lee, J. P. Warrington, W. E. Sonntag, and Y. W. Lee,
“Irradiation alters MMP-2/TIMP-2 system and collagen type
IV degradation in brain,” International Journal of Radiation
Oncology Biology Physics, vol. 82, no. 5, pp. 1559–1566, 2012.
[29] S. C. Thal, C. Luh, E. V. Schaible et al., “Volatile anesthetics
influence blood-brain barrier integrity by modulation of tight
junction protein expression in traumatic brain injury,” PLoS
One, vol. 7, no. 12, Article ID e50752, 2012.
[30] M. J. Fabis, G. S. Scott, R. B. Kean, H. Koprowski, and D. C.
Hooper, “Loss of blood-brain barrier integrity in the spinal
cord is common to experimental allergic encephalomyelitis in
knockout mouse models,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 104, no. 13, pp.
5656–5661, 2007.
10 Mediators of Inflammation
[31] K. Wosik, R. Cayrol, A. Dodelet-Devillers et al., “Angiotensin
II controls occludin function and is required for blood-brain
barrier maintenance: relevance to multiple sclerosis,” Journal of
Neuroscience, vol. 27, no. 34, pp. 9032–9042, 2007.
[32] D. H. Yang, Z. Y. Ye, Y. J. Xie, X. J. He, W. J. Xu, and W.
M. Zhou, “Effect of salvianolate on intestinal epithelium tight
junction protein zonula occludens protein 1 in cirrhotic rats,”
World Journal of Gastroenterology, vol. 18, no. 47, pp. 7040–7047,
2012.
[33] J. Bennett, J. Basivireddy, A. Kollar et al., “Blood-brain barrier
disruption and enhanced vascular permeability in the multiple
sclerosismodel EAE,” Journal of Neuroimmunology, vol. 229, no.
1-2, pp. 180–191, 2010.
[34] G. A. Rosenberg, “Matrix metalloproteinases and neuroinflam-
mation in multiple sclerosis,” Neuroscientist, vol. 8, no. 6, pp.
586–595, 2002.
[35] M. D. Sternlicht and Z. Werb, “How matrix metalloproteinases
regulate cell behavior,”Annual Review ofCell andDevelopmental
Biology, vol. 17, pp. 463–516, 2001.
[36] Y. Yang, E. Y. Estrada, J. F. Thompson, W. Liu, and G. A. Rosen-
berg, “Matrix metalloproteinase-mediated disruption of tight
junction proteins in cerebral vessels is reversed by synthetic
matrix metalloproteinase inhibitor in focal ischemia in rat,”
Journal of Cerebral Blood Flow and Metabolism, vol. 27, no. 4,
pp. 697–709, 2007.
[37] A. T. Bauer, H. F. Bu¨rgers, T. Rabie, and H. H. Marti, “Matrix
metalloproteinase-9 mediates hypoxia-induced vascular leak-
age in the brain via tight junction rearrangement,” Journal of
Cerebral Blood Flow andMetabolism, vol. 30, no. 4, pp. 837–848,
2010.
[38] K. Jovanova-Nesic and Y. Shoenfeld, “MMP-2, VCAM-1 and
NCAM-1 expression in the brain of rats with experimental
autoimmune encephalomyelitis as a trigger mechanism for
synaptic plasticity and pathology,” Journal of Neuroimmunology,
vol. 181, no. 1-2, pp. 112–121, 2006.
[39] G. Opdenakker, I. Nelissen, and J. Van Damme, “Functional
roles and therapeutic targeting of gelatinase B and chemokines
in multiple sclerosis,” Lancet Neurology, vol. 2, no. 12, pp. 747–
756, 2003.
[40] J. Sellner, F. Simon, U. Meyding-Lamade, and S. L. Leib,
“Herpes-simplex virus encephalitis is characterized by an early
MMP-9 increase and collagen type IV degradation,” Brain
Research, vol. 1125, no. 1, pp. 155–162, 2006.
[41] R. K.Dore, “How to prevent glucocorticoid-induced osteoporo-
sis,” Cleveland Clinic Journal of Medicine, vol. 77, no. 8, pp. 529–
536, 2010.
[42] C. Gennari, “Differential effect of glucocorticoids on calcium
absorption and bone mass,” British Journal of Rheumatology,
vol. 32, no. 2, pp. 11–14, 1993.
[43] M. K.-S. Leow, D. S.-K. Kwek, A. W.-K. Ng, K.-C. Ong, G. J.-L.
Kaw, and L. S.-U. Lee, “Hypocortisolism in survivors of severe
acute respiratory syndrome (SARS),” Clinical Endocrinology,
vol. 63, no. 2, pp. 197–202, 2005.
[44] A. Minagar, A. H. Maghzi, J. C. McGee, and J. S. Alexander,
“Emerging roles of endothelial cells in multiple sclerosis patho-
physiology and therapy,” Neurological Research, vol. 34, no. 8,
pp. 738–745, 2012.
